Showing 1 - 6 results of 6 for search 'Yuee Teng', query time: 0.01s Refine Results
  1. 1
    Role of patient-, tumor- and –related factors in predicting survival of patients with node-negative gastric cancer

    Role of patient-, tumor- and –related factors in predicting survival of patients with node-negative gastric cancer by Jinglei Qu, Xiujuan Qu, Zhi Li, Jingdong Zhang, Yuee Teng, Bo Jin, Mingfang Zhao, Ping Yu, Zhenning Wang, Yunpeng Liu

    Published 2017-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer

    PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer by Xin Zhao, Yang Li, Hongyan Zhang, Yihang Cai, Xu Wang, Yidu Liu, Tingting Li, Chendong Xu, Yuee Teng, Danni Li, Feng Li

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study

    A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive heavily pretreated solid tumors: results from a phase Ia/Ib first-in-human, open-label, single center study by Na Song, Na Song, Yuee Teng, Yuee Teng, Jing Shi, Jing Shi, Zan Teng, Zan Teng, Bo Jin, Bo Jin, Jinglei Qu, Jinglei Qu, Lingyun Zhang, Lingyun Zhang, Ping Yu, Ping Yu, Lei Zhao, Lei Zhao, Jin Wang, Jin Wang, Aodi Li, Aodi Li, Linlin Tong, Linlin Tong, Shujie Jiang, Shujie Jiang, Yang Liu, Yang Liu, Liusong Yin, Xiaoling Jiang, Tie Xu, Jian Cui, Xiujuan Qu, Xiujuan Qu, Yunpeng Liu, Yunpeng Liu

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

    An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 tri... by Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis

    Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis by Jiayu Wang, Qingyuan Zhang, Huiping Li, Zhongsheng Tong, Quchang Ouyang, Huihui Li, Yuee Teng, Biyun Wang, Tao Sun, Jingfen Wang, Wei Li, Zhaofeng Niu, Hongsheng Li, Chang Gong, Shu Wang, Xinshuai Wang, Xinhong Wu, Ning Liu, Guohua Yu, Fei Liu, Xianghui Duan, Shuya Wang, Yaping Meng, Li Wang, Binghe Xu

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort

    Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort by Xichun Hu, Qingyuan Zhang, Tao Sun, Huihua Xiong, Wei Li, Yuee Teng, Yen-Shen Lu, Ling-Ming Tseng, Min Yan, Hongsheng Li, Danmei Pang, Shin-Cheh -Chen, Wenyan Chen, Ou Jiang, Jingfen Wang, Xinhong Wu, Xian Wang, Aimin Zang, Xiaojia Wang, Julie M. Collins, Ethan Fan, Lin Jiang, Xiaoling Zeng, Nicholas C. Turner

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: